{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:33:47Z","timestamp":1762018427868},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,2]]},"DOI":"10.7759\/cureus.24661","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T10:24:57Z","timestamp":1651487097000},"source":"Crossref","is-referenced-by-count":2,"title":["Use of Proton Pump Inhibitors With Dexamethasone in Patients With COVID-19 Pneumonia: Contributions to Long-Term Polypharmacy"],"prefix":"10.7759","author":[{"given":"Ranbir","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megha","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198307073090105","article-title":"Association of adrenocorticosteroid therapy and peptic-ulcer disease","volume":"309","author":"Messer J","year":"1983","unstructured":"Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med. 1983, 309:21-4. 10.1056\/NEJM198307073090105","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-9-735","article-title":"Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs","volume":"114","author":"Piper JM","year":"1991","unstructured":"Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991, 114:735-40. 10.7326\/0003-4819-114-9-735","journal-title":"Ann Intern Med"},{"key":"ref4","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. (2022). Accessed. 3\/22\/22: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz PO","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022, 117:27-56. 10.14309\/ajg.0000000000001538","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/8755122515575177","article-title":"Review of proton pump inhibitor overuse in the US veteran population","volume":"31","author":"Metaxas ES","year":"2015","unstructured":"Metaxas ES, Bain KT. Review of proton pump inhibitor overuse in the US veteran population. J Pharm Technol. 2015, 31:167-76. 10.1177\/8755122515575177","journal-title":"J Pharm Technol"},{"key":"ref7","article-title":"Polypharmacy: evaluating risks and deprescribing","volume":"100","author":"Halli-Tierney AD","year":"2019","unstructured":"Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. American Family Physician . 2019, 100:32-8.","journal-title":"American Family Physician"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G703","article-title":"Acid suppressive therapy use on an inpatient internal medicine service","volume":"40","author":"Pham CQ","year":"2006","unstructured":"Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006, 40:1261-6. 10.1345\/aph.1G703","journal-title":"Ann Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-006-9028-4","article-title":"Continuation of proton pump inhibitors from hospital to community","volume":"28","author":"Grant K","year":"2006","unstructured":"Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006, 28:189-93. 10.1007\/s11096-006-9028-4","journal-title":"Pharm World Sci"},{"key":"ref10","article-title":"Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting","volume":"16","author":"Heidelbaugh JJ","year":"2010","unstructured":"Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010, 16:228-34.","journal-title":"Am J Manag Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.10.013","article-title":"A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors","volume":"124","author":"Naggie S","year":"2011","unstructured":"Naggie S, Miller BA, Zuzak KB, et al.. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2011, 124:276.e1-7. 10.1016\/j.amjmed.2010.10.013","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04453.x","article-title":"Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study","volume":"32","author":"Keszthelyi D","year":"2010","unstructured":"Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010, 32:1124-8. 10.1111\/j.1365-2036.2010.04453.x","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/94499-use-of-proton-pump-inhibitors-with-dexamethasone-in-patients-with-covid-19-pneumonia-contributions-to-long-term-polypharmacy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:48Z","timestamp":1707507528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/94499-use-of-proton-pump-inhibitors-with-dexamethasone-in-patients-with-covid-19-pneumonia-contributions-to-long-term-polypharmacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.24661","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,2]]}}}